TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00343863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nausea and vomiting therapy
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nausea and vomiting therapy
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study: NCT04304794

Intervention type: PROCEDURE
Intervention: Administration of iodinated contrast media
Description: Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.

Intervention type: PROCEDURE
Intervention: Administration of iodinated contrast media
Description: Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.

Intervention type: DRUG
Intervention: Prophylactic administration of antithyroid drugs before iodinated contrast media exposure
Description: 13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
Study: NCT03855202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBMNC
Description: autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PS+CBMNC
Description: autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PS
Description: PS,dose is 70mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placeo
Description: 0.9% sodium chloride installation after 24 hours
Study: NCT02876874

Intervention type: DRUG
Intervention: indocyanine green(ICG)
Description: ICG will be injected into the dorsal of hand/foot

Intervention type: DRUG
Intervention: indocyanine green(ICG)
Description: ICG will be injected into the dorsal of hand/foot
Study: NCT03527628

Intervention type: DRUG
Group type: OTHER
Intervention: Adriamycin
Description: 25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Adriamycin
Description: 25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
Study: NCT03131713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1000mg
Study: NCT03864016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction and maintenance of anesthesia
Description: The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.

Intervention type: DRUG
Group type: OTHER
Intervention: Induction and maintenance of anesthesia
Description: The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
Study: NCT03527628

Intervention type: DRUG
Group type: OTHER
Intervention: Vinblastine
Description: 6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
Study: NCT04419207

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
Study: NCT03527628

Intervention type: DRUG
Group type: OTHER
Intervention: Vinblastine
Description: 6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Dacarbazine
Description: 375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Dacarbazine
Description: 375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
Study: NCT02160301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: PO
Study: NCT00569439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5NS
Description: 5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
Study: NCT03527628

Intervention type: DRUG
Group type: OTHER
Intervention: Brentuximab Vedotin
Description: 1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
Study: NCT05021666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group
Study: NCT03527628

Intervention type: DRUG
Group type: OTHER
Intervention: ABVD
Description: All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)

Intervention type: DRUG
Group type: OTHER
Intervention: ABVD
Description: All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
Study: NCT01356732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
Study: NCT01134926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 8oo mcg intravaginal, second dose after one day if there is no response
Study: NCT01459367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks.
Study: NCT00382915

Intervention type: DEVICE
Intervention: CReSSmicro handheld topography device
Description: The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.

Intervention type: DEVICE
Intervention: CReSSmicro handheld topography device
Description: The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.

Intervention type: DEVICE
Intervention: CReSSmicro handheld topography device
Description: The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
Study: NCT00569439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D10NS
Description: 10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
Study: NCT02604212

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study: NCT00598663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)
Description: 6 months of pump plus continuous glucose sensing in conjunction to SMBG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)
Description: insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
Study: NCT00720057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAYH6689)
Description: Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
Study: NCT00641862

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
Study: NCT01892501

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Guided punction of mediastinal lymphadenopathy by echoendoscopy
Description: EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken.

Intervention type: DEVICE
Group type: OTHER
Intervention: PET scan
Description: The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
Study: NCT04443504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Connected Family Series
Description: The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
Study: NCT03505944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: venetoclax + lenalidomide + rituximab
Study: NCT02671279

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low calorie diet
Description: 6 days of low calorie diet, estimated kcal 400-600/day.
Study: NCT01032876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Hypothermic Circulatory Arrest
Description: DHCA will be employed for a maximum of 60 minutes. If more time (\>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antegrade Cerebral Perfusion
Description: One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
Study: NCT01733407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-serine
Description: 400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 400mg/kg/d divided TID for year 1 only.
Study: NCT00569439

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS
Description: Normal Saline solution at 125 cc/hr
Study: NCT03096470

Intervention type: PROCEDURE
Intervention: anesthesia
Description: no anesthesia

Intervention type: PROCEDURE
Intervention: anesthesia
Description: no anesthesia
Study: NCT03630549

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Clinic-based HIV care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Village-based ART refill
Description: Option to get ART refill and care by the village health worker
Study: NCT04252638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy plus Sleep Restriction
Description: Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy including Sleep Restriction
Description: CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
Study: NCT02105571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Study: NCT05021666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group
Study: NCT00979004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICA-105665
Description: Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
Study: NCT02808273

Intervention type: DRUG
Intervention: Bemiparine
Description: Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
Study: NCT00215904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D-serine (~2g/day)
Description: Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine (~2g/day)
Description: Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
Study: NCT03513432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beer with 5.20 % alcohol
Description: 330 ml beer (5.20 % alcohol)/day during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beer with 0.45 % alcohol
Description: 330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beer with 0.00 % alcohol
Description: 330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
Study: NCT02714894

Intervention type: DRUG
Intervention: Clozapine
Description: Patient participants will be starting clozapine as part of their clinical care.

Intervention type: DRUG
Intervention: Clozapine
Description: Patient participants will be starting clozapine as part of their clinical care.
Study: NCT01843933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capnography
Description: Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
Study: NCT03799523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporary skin markings
Description: To use temporary markings in lieu of localization tattoos.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface imaging
Description: To use light-based surface imaging for patient positioning during radiation treatment.
Study: NCT02411994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Study: NCT02116192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Low-fructose, reduced carbohydrate diet
Description: Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Healthy Diet
Description: Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
Study: NCT02659839

Intervention type: OTHER
Intervention: Cancer patients admitted to the ICU
Description: There will be no change in the standard ICU treatment.
Study: NCT03276494

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraosseous
Description: Intraosseous administration of hypertonic saline

Intervention type: DRUG
Group type: OTHER
Intervention: Hypertonic saline
Description: Intraosseous administration of hypertonic saline
Study: NCT00018694

Intervention type: DRUG
Group type: OTHER
Intervention: Chenodeoxycholic Acid
Study: NCT01070381

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A contact lens
Description: Commercially marketed, toric, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A contact lens
Description: Commercially marketed, toric, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: ocufilcon D contact lens
Description: Commercially marketed, toric, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: ocufilcon D contact lens
Description: Commercially marketed, toric, soft contact lens for daily disposable wear
Study: NCT01869686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 60 mg